MedTrace Logo

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

NCT01277991 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-04-07

No results posted yet for this study

Summary

In this study, a 5 mg dose of CP-690,550 will be given to study subjects on two separate occasions using one of two different strength tablets each time. The amount of CP-690,550 available in the blood following administration of each tablet will be measured and compared. The overall aim of the study is to establish that a similar amount of CP-690,550 is absorbed into the blood following administration of the same dose of each different strength tablet .

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

DRUG

Treatment B

Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)

DRUG

Treatment A

Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277991 on ClinicalTrials.gov